ストックスクリーナーアプリを入手
34.45
3.45%
1.15
アフターアワーズ：
34.45
前日終値:
$33.30
開ける：
$33.28
24時間の取引高:
572.16K
Relative Volume:
0.63
時価総額：
$2.02B
収益：
$54.03M
当期純損益:
$-412.78M
株価収益率:
-4.8392
EPS:
-7.1189
ネットキャッシュフロー:
$-377.29M
1週間 パフォーマンス:
+2.01%
1か月 パフォーマンス:
+23.70%
6か月 パフォーマンス:
-16.75%
1年 パフォーマンス:
+23.83%
1日の値動き範囲:
$33.23
$34.48
1週間の範囲:
$32.47
$34.48
52週間の値動き範囲:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
34.45 | 1.95B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Trend Review: Will Agios Pharmaceuticals Inc face regulatory challengesQuarterly Growth Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Valuation Update: Is Agios Pharmaceuticals Inc stock good for income investorsExit Point & Fast Moving Stock Trade Plans - baoquankhu1.vn
Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036 - GlobeNewswire Inc.
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ADVFN
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion - MSN
Published on: 2026-04-10 10:39:14 - baoquankhu1.vn
Exit Recap: Is Agios Pharmaceuticals Inc stock good for income investors2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
What Agios Pharmaceuticals (AGIO)'s FDA-Backed Accelerated Path for Mitapivat in Sickle Cell Disease Means For Shareholders - Sahm
(AGIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - AOL.com
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals Insider Sells $102,047 in Stock - National Today
Agios Pharmaceuticals Insider Sells $102K in Shares - National Today
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $113,848.80 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Cecilia Jones Sells 3,141 Shares - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $113,224.02 in Stock - marketbeat.com
AGIO: JP Morgan Raises Price Target to $36, Maintains Neutral Ra - GuruFocus
Agios Pharmaceuticals CLO sells $113,848 in stock By Investing.com - Investing.com Canada
Jones Cecilia, Agios Pharmaceuticals CFO, sells $109k in stock By Investing.com - Investing.com India
Jones Cecilia, Agios Pharmaceuticals CFO, sells $109k in stock - Investing.com
Agios (NASDAQ: AGIO) CLO exercises 8,500 PSUs and sells shares for taxes - Stock Titan
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Agios (NASDAQ: AGIO) CFO exercises PSUs, automatic share sale for taxes - Stock Titan
Agios (AGIO) CCO vests 8,500 PSUs, sells 3,262 shares for taxes - Stock Titan
Agios (NASDAQ: AGIO) exec sells shares to cover PSU tax obligations - Stock Titan
Agios (AGIO) CEO settles performance units, sells 19K shares to cover taxes - Stock Titan
JPMorgan Chase & Co. Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $36.00 - MarketBeat
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET - Bitget
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $36 - Moomoo
Short Squeeze: Is Agios Pharmaceuticals Inc stock overvalued or fairly priced2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Agios to Host First Quarter 2026 Financial Results Conference Call - National Today
Agios will webcast first-quarter results before markets open April 29 - Stock Titan
A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat - Sahm
AGIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance Australia
Agios to seek accelerated approval in US of oral mitapivat for SCD - Sickle Cell Disease News
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
AGIO (NASDAQ: AGIO) pre-sale notice — 3,141 RSU shares vesting - Stock Titan
Insider sale and RSU vesting at AGIO (Nasdaq: AGIO) — 2,959 shares - Stock Titan
RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting - Stock Titan
3,280 RSUs vest; James Burns sold 5,218 shares — AGIO (NASDAQ: AGIO) - Stock Titan
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
AGIO Shares Climb as Mitapivat Advances Toward Fast-Track Approval for SCD - bitget.com
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Finviz
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - Yahoo Finance
Earnings Recap: Is Agios Pharmaceuticals Inc a good ESG investment2026 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):